-
This randomized, controlled, open-label, multicenter Phase 3 trial compared axitinib with sorafenib as second-line therapy for metastatic renal clear-cell cancer. The results showed that axitinib extended progression-free survival by 2 months more than sorafenib (6.7 months vs 4.7 months), and had a superior objective response rate (19.4% vs 9.4%).
-
An asymptomatic 78-year-old retired accountant presented to his physician with intractable hiccups. Physical examination, complete blood count, and imaging studies did not reveal a cause of the hiccups, and after several days the symptom disappeared. However, upon review of the abdominal CT scan obtained in evaluation of the hiccups, a right renal mass was defined.
-
New treatment for prostate cancer; avastin and breast cancer; new CMS disclosure rule; and FDA actions.
-
Ulipristal acetate, the drug recently approved as an emergency contraceptive in the United States (Ella, Watson Pharmaceuticals, Morristown, NJ), is being eyed for other gynecologic uses. In research looking at women with symptomatic fibroids who were planning to undergo surgery, treatment with the selective progesterone-receptor modulator was effective in controlling excessive bleeding and reducing fibroid size at 13 weeks.
-
Results from a large, long-running Scandinavian study provides convincing evidence that combined oral contraceptives (OCs) alleviate the symptoms of dysmenorrhea, painful menstrual periods.
-
New research indicates that the human papillomavirus vaccine (HPV) Gardasil (Merck & Co.) does not trigger autoimmune conditions such as lupus, rheumatoid arthritis, type 1 diabetes, or multiple sclerosis after vaccination in young women.
-
Has your clinic telephone been ringing recently with calls from women who have heard about a birth control pill recall? Chances are, few, if any, of your patients were using the affected oral contraceptives (OCs).
-
Where do long-acting reversible contraceptives (LARC) fit in at your facility? How are you encouraging women to use the "Get It and Forget It" methods? If you are seeing low numbers of women choosing intrauterine devices (IUDs) or the contraceptive implant, you might want to change your counseling strategy.
-
Now that male circumcision has been associated with a lower risk for HIV infection in international observational studies and in three randomized controlled clinical trials, international health officials are looking at options in making it more available to men at risk.
-
The results of the PEARL I and PEARL II studies were published recently in the same issue of the New England Journal of Medicine. Both were well-designed, randomized, controlled, double-blinded studies that assessed the safety and efficacy of ulipristal acetate (UPA) for the treatment of symptomatic uterine fibroids.
